In this study, we show that a serum-stable, cell-penetrating, oligonucleotide-condensing, endosomolytic peptide-based NP system can deliver siRNA against KRAS to KRAS-driven cancers, reducing KRAS pathway expression, and slowing KRAS-driven pancreatic cancer growth in vivo. Here, KRAS is linked to familial pancreatic carcinoma.